Orion
§ CompareIncretin / GLP-1-class research compounds

Retatrutide vs Tirzepatide

Retatrutide and Tirzepatide are both investigational incretin-class peptides studied for metabolic-signaling research. They differ in receptor coverage (triple agonist vs dual agonist), sequence, and reported half-life.

Research Use Only

Comparison information is provided for in-vitro research reference only. Orion compounds are not FDA-approved and are not for human consumption.

RetatrutideTirzepatide
CAS Number2381089-83-22023788-19-2
Molecular Weight4625.27 g/mol4813.48 g/mol
Sequence
Purity (spec)99.0%98.8%
Size10mg10mg
Half-Life (lit.)144h (lit. 120h–168h)120h (lit. 108h–132h)
Single price$54.99$44.99
10-pack/vial$41.24$33.74
In stock?YesYes

FAQ

What's the chemical difference between Retatrutide and Tirzepatide?

Retatrutide (CAS 2381089-83-2, MW 4625.27 g/mol) and Tirzepatide (CAS 2023788-19-2, MW 4813.48 g/mol) are distinct compounds. Retatrutide and Tirzepatide are both investigational incretin-class peptides studied for metabolic-signaling research. They differ in receptor coverage (triple agonist vs dual agonist), sequence, and reported half-life.

Which is more commonly used in research?

Both Retatrutide and Tirzepatide appear extensively in Incretin / GLP-1-class research compounds literature. Comparative-mechanism studies frequently use them as paired references. Selection between them depends on the receptor coverage, kinetics, and assay system of the planned experiment.

What purity does Orion ship for each?

Retatrutide ships at 99.0%. Tirzepatide ships at 98.8%. Each batch is independently tested by reversed-phase HPLC and confirmed by mass spectrometry against the theoretical molecular weight. Every order ships with a batch-specific Certificate of Analysis.

Are these for human use?

No. All Orion research compounds are for in-vitro laboratory research only. They are not FDA-approved for any therapeutic, diagnostic, or clinical use, and they are not for human consumption.

Other comparisons